OTC Markets OTCPK - Delayed Quote USD

Nykode Therapeutics AS (VACBF)

0.3150

+0.0742

+(30.81%)

At close: January 23 at 7:00:00 PM EST

DISA Leads The Charge With These 3 Penny Stocks

With global markets experiencing volatility amid cautious Federal Reserve commentary and political uncertainty, investors are closely monitoring opportunities that can offer potential value. In this context, penny stocks—often seen as relics of past market eras—continue to capture interest due to their affordability and growth potential. These smaller or newer companies can provide a unique combination of value and stability when backed by strong financials, making them intriguing options for...

Simply Wall St. last month

SKL.NZ

VACBF
+30.81%
Nykode Therapeutics And 2 More Penny Stocks Worth Watching

As global markets navigate the implications of the incoming Trump administration, investors are closely watching sectors influenced by potential policy shifts. In this context, penny stocks—typically smaller or newer companies—remain a compelling area for exploration due to their potential for growth at lower price points. Despite being an outdated term, these stocks can offer significant opportunities when backed by strong financials and solid fundamentals, making them worthy of attention in...

Simply Wall St. 2 months ago

VACBF
+30.81%
SCANA.OL

SCANAO.OL
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe

OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its APC-targeted inverse vaccine platform’s efficacy in treating autoimmune disease at the annual PEGS Europe conference in Barcelona. The data presented emphasize the role of antigen-presenting cell (APC) targeting in achieving therapeutic effectiveness, particu

GlobeNewswire 2 months ago

VACBF
+30.81%
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines

OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,059,459, entitled, “Therapeutic Anticancer Neoepitope Vaccine”. The newly issued patent describes Nykode’s fully individualized neoantigen based vaccine, VB10.NEO, which is in development for the tr

GlobeNewswire 5 months ago

VACBF
+30.81%
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced advancements in its inverse vaccine platform at the annual Federation of Clinical Immunology Societies (FOCIS) meeting in San Francisco. Building on findings previously announced in March at the Antigen-Specific Immune Tolerance Summit in Boston, Nykode presented extended therapeutic da

GlobeNewswire 7 months ago

VACBF
+30.81%
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced updates on its mRNA platform at the Cancer Immunotherapy meeting in Boston. The company highlighted the significant advantages of its innovative APC-targeted neoantigen vaccine, delivered in a mRNA-lipid nanoparticle (LNP) format. This latest study demonstrated that the APC-targeted vac

GlobeNewswire 7 months ago

VACBF
+30.81%
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has expanded its collaboration with MSD (Merck & Co., Inc., Rahway, NJ, USA) to include a clinical trial collaboration and supply agreement for a phase 2 trial evaluating Nykode’s wholly-owned lead candidate, VB10.16, in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembro

GlobeNewswire 8 months ago

VACBF
+30.81%
Nykode Therapeutics - Quarterly report Q1 2024

OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024. The financial report can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations. The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET

GlobeNewswire 8 months ago

VACBF
+30.81%
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq®1) in patients with HPV16-po

GlobeNewswire 9 months ago

VACBF
+30.81%
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Updated survival data from Phase 2 trial (C-02) in advanced cervical cancer affirm prolonged benefits and indicate a synergistic treatment effect of Nykode’s VB10.16 and atezolizumab (Tecentriq®).New analysis closely mirrors previously reported positive outcome. At the time of the updated analysis, observation time for remaining patients was at least 24 months compared to at least 12 months at the previous reported outcome. Updated C-02 survival data support the accelerated development of VB10.1

GlobeNewswire 10 months ago

VACBF
+30.81%
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced key updates of the inverse vaccine platform with the potential to treat autoimmune diseases at the 7th Antigen-Specific Immune Tolerance Drug Development Summit in Boston. Nykode employs its unique technology platform to pioneer the field of inverse vaccines, with the potential to deve

GlobeNewswire 10 months ago

VACBF
+30.81%

Performance Overview

Return	VACBF	OBX Total Return Index
YTD	0.00%	+7.37%
1-Year	-84.76%	+22.27%
3-Year	-89.48%	+35.92%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Nykode Therapeutics AS (VACBF)

DISA Leads The Charge With These 3 Penny Stocks

Nykode Therapeutics And 2 More Penny Stocks Worth Watching

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe

Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines

Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting

Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy

Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer

Nykode Therapeutics - Quarterly report Q1 2024

Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer

Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer

Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases

Performance Overview